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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Padina pavonica-extract in Dictyolone
®
 and an increase in bone mineral 
density pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from ICP Ltd, submitted for authorisation of a health claim pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to Padina pavonica-extract in Dictyolone
®
 and an increase in bone mineral density. The Panel considers 
that the Padina pavonica-extract in Dictyolone
®
 is sufficiently characterised. An increase (or reduced loss) in 
bone mineral density is a beneficial physiological effect. The applicant presented four human intervention 
studies, four animal studies and two in vitro studies as pertinent to the health claim. No conclusions could be 
drawn from two of the four human studies as they were carried out with a food that did not comply with the 
specifications of the food which is the subject of the health claim. The two other human studies did not show an 
effect of the Padina pavonica-extract in Dictyolone
®
 on bone mineral density. The Panel concludes that a cause 
and effect relationship has not been established between the consumption of Padina pavonica-extract in 
Dictyolone
®
 and an increase (or reduced loss) in bone mineral density. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from ICP Ltd, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Malta, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to Padina pavonica-extract in Dictyolone
®
 and an 
increase in bone mineral density (BMD). 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is a Padina pavonica-extract in Dictyolone
®
. The 
starting material for the extraction process is dried Padina pavonica, which is a brown alga commonly 
known as Peacock’s tail. The Panel considers that the Padina pavonica-extract in Dictyolone® is 
sufficiently characterised. 
The claimed effect is “improves bone density”. The target population proposed by the applicant is the 
general population. The Panel considers that an increase (or reduced loss) in bone mineral density is a 
beneficial physiological effect. 
The applicant presented four human intervention studies, four animal studies and two in vitro studies 
as pertinent to the health claim. 
Two of the four human intervention studies were carried out with a food (i.e. lyophilised powder of 
Padina pavonica) that did not comply with the specifications of the food (i.e. Padina pavonica-
extract in Dictyolone
®
) which is the subject of the health claim. The Panel considers that no 
conclusions can be drawn from these two studies for the scientific substantiation of a health claim on 
the Padina pavonica-extract in Dictyolone
®
. 
In a randomised, open label, parallel human study, 40 post-menopausal women were randomised into 
two groups to receive daily for 12 months 200 mg Padina pavonica-extract in Dictyolone
®
 plus 
450 mg calcium carbonate or 450 mg calcium carbonate only. The primary outcome of the study was 
BMD which was measured at the screening visit and at the end of the study (i.e. at month 12) at the 
lumbar region and at the left hip region (femoral neck). In addition, bone turnover markers were 
measured at month 3 and month 6. There were no statistically significant differences for percent 
changes in BMD at either site (i.e. lumbar region or femoral neck) between the groups. There were no 
differences in bone turnover markers between the groups. The Panel notes that this study did not show 
an effect of the Padina pavonica-extract in Dictyolone
®
 on BMD. 
In another randomised, open label, parallel human study, 40 post-menopausal women were 
randomised into two groups to receive daily for 12 months 200 mg Padina pavonica-extract in 
Dictyolone
®
 or 450 mg calcium carbonate. The same protocol as for the above study was followed 
except that BMD measurements were performed three times, i.e. at the screening (= baseline), and at 
month 6 and month 12. Bone turnover markers were not assessed in this study. Absolute values of 
BMD were transformed to percent changes of BMD prior to hypothesis testing. When using the Mann 
Whitney test, after 12 months the BMD was increased (as percent change from baseline) in the group 
which had consumed the Padina pavonica-extract in Dictyolone
®
 in lumbar spine and in the femoral 
neck, when compared with the control group. When an analysis of variance (ANOVA) was performed 
on such transformed (i.e. percent changes) data, a statistically significant difference between the 
placebo and the Padina pavonica-group was found at the femoral neck only and not at the lumbar 
spine. When ANOVA was performed with absolute values of BMD, there were no statistically 
significant differences between the placebo and the Padina pavonica group at any time point. The 
repeated measures design was not taken into account in any of the provided analyses. The Panel notes 
the limitations of the statistical analyses performed by the applicant (i.e. transformation of data, lack 
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of baseline adjustments in the analysis of absolute values, lack of consideration of the repeated 
measures design of the study) and that the requested re-analysis of data addressing these limitations 
was not presented by the applicant. The Panel also notes that the results of the different statistical 
analyses, i.e. percent change in BMD analysed with the Mann Whitney test and ANOVA, and 
absolute values of BMD analysed with ANOVA, were inconsistent both between the different 
statistical tests and between bone sites investigated. The Panel considers that this study did not show 
an effect of the Padina pavonica-extract in Dictyolone
®
 on BMD. 
The provided animal studies did not evaluate BMD. The in vitro studies measured calcium 
accumulation in primary and cell-line osteoblasts. 
In weighing the evidence, the Panel took into account that the two human studies from which 
conclusions could be drawn for the scientific substantiation of the claim did not show an effect of the 
Padina pavonica-extract in Dictyolone
®
 on BMD. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Padina pavonica-extract in Dictyolone
®
 and an increase (or reduced loss) in BMD. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 25/02/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 22/03/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 30/04/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 15/05/2013. 
 On 26/06/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 17/07/2013, in compliance with Article 18(3) of Regulation (EC) 
No 1924/2006. 
 On 30/07/2013, EFSA received the requested information and the clock was restarted, in 
compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 On 25/09/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 04/10/2013, in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
 On 16/10/2013, EFSA received the requested information and the clock was restarted, in 
compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 During its meeting on 11/12/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to 
Padina pavonica-extract in Dictyolone
®
 and an increase (or reduced loss) in bone mineral 
density. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Padina pavonica-extract in 
Dictyolone
®
 and an increase in bone mineral density. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of the Padina pavonica-extract in Dictyolone
®
, a positive assessment of its safety, nor a 
decision on whether the Padina pavonica-extract in Dictyolone
®
 is, or is not, classified as a foodstuff. 
It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 
1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
Padina pavonica-extract in Dictyolone® and bone mineral density  
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Institute of Cellular Pharmacology (ICP) Ltd, Unit F24/F25, 
MOSTA Technopark, Malta. 
The application includes a request for the protection of proprietary data for three unpublished animal 
studies (Gutierrez et al., 2006a, b, 2011) and two in vitro studies (Gutierrez, 2006; Serrar et al., 
unpublished) in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is Dictyolone
®
 which has as 
its constituent a known quantity of Padina pavonica-extract. Padina pavonica is a brown alga with a 
worldwide distribution. 
Health relationship as claimed by the applicant 
According to the applicant, Padina pavonica exhibits a “calcitrophic” effect, which is brought about 
by the synthesis and release of a substance that affects “fixation” of calcium. The applicant claimed 
that this would lead to an increase in bone mineral density (BMD). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “improves bone density 
through calcitrophic effects and through the physiological restoration of proteinous bone, particular in 
bone loss brought about by the aging process on normal healthy persons”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed a daily intake of 200 to 400 mg of Padina pavonica-extract, possibly in 
several doses, for an average body weight of about 50 to 60 kg. The target population is the general 
population. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is a Padina pavonica-extract in Dictyolone
®
. 
The starting material for the extraction process is dried Padina pavonica, which is a brown alga 
commonly known as Peacock’s tail. For the extraction, lower alkanols (e.g. ethanol) or aliphatic 
ketones (e.g. acetone) are used. An overview of the patented manufacturing process (EP 0 655 250 
B1; US 5,961,981 B2) was provided. 
Each tablet of Dictyolone
®
 contains, on average, the extract of 500 mg of dry plant, which 
corresponds to 5 g of fresh plant, plus the excipients magnesium stearate, microcrystalline cellulose, 
silicon dioxide and talc. 
The extract is standardised to its capacity to increase intracellular calcium (denominated as “calcium-
fixation” by the applicant) in vitro in human osteoblasts (G292 cell line) following a patented 
procedure (FR 2 827 303; US 7,122,337 B2). 
Padina pavonica-extract in Dictyolone® and bone mineral density  
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The Panel considers that the food, the Padina pavonica-extract in Dictyolone
®
, which is the subject of 
the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “increase in bone mineral density”. The target population proposed by the 
applicant is the general population. 
Contribution to the development and maintenance of normal bone throughout the lifespan is 
considered to be a beneficial physiological effect (EFSA NDA Panel, 2012). An increase in bone 
formation and/or a decrease in bone resorption are considered beneficial physiological effects when 
they lead to an increase (or reduced loss) in bone mineral density (BMD). 
The Panel considers that an increase (or reduced loss) in bone mineral density is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in the company’s own archive and database, where all 
bibliography deemed relevant by the applicant was claimed to be catalogued. Inclusion and exclusion 
criteria were “based on the relevance of the data presented in relation to the claim brought forward”. 
All the documents retrieved were considered to be relevant by the applicant, since they were “related 
to the physiological effect of the Padina pavonica at cellular level related to calcium fixation”. 
The applicant presented four human intervention studies (Galea, 2009, PhD thesis), four animal 
studies (Gutierrez et al., 2005, 2006a, b, 2011; all four unpublished) and two in vitro studies (Serrar et 
al., unpublished; Gutierrez, 2006) as pertinent to the health claim. 
Two of the four human intervention studies reported by Galea (2009) were carried out with a 
lyophilised powder (obtained before the extraction process) of Padina pavonica that does not comply 
with the specifications of the food (as described in section 1) which is the subject of the health claim. 
The applicant was requested to provide a rationale as to why results from studies with the lyophilised 
powder could be used for the substantiation of a health claim on the extract. In reply, the applicant 
stated that the studies which were carried out with the lyophilised powder of Padina pavonica were 
used to “help determine the effective minimal dose and help determine the interference the calcium 
carbonate had in the makeup of the capsule”. The Panel considers that no conclusions can be drawn 
from the two studies carried out with a lyophilised powder of Padina pavonica for the scientific 
substantiation of a health claim on the Padina pavonica-extract in Dictyolone
®
. 
In a randomised, open label, parallel human study (Galea, 2009) 40 post-menopausal women 
attending a bone densitometry unit in a hospital in Malta were randomised into two groups to receive 
daily for 12 months 200 mg Padina pavonica-extract in Dictyolone
®
 plus 450 mg calcium carbonate 
(= 180 mg Ca) (mean age 59.3 ± 5.8 years, mean age of menopause 50.4 ± 2.6 years) or 450 mg 
calcium carbonate only (control group, mean age 58.0 ± 7.5 years, mean age of menopause 
50.0 ± 2.9 years). Women were included if they either were postmenopausal for at least five years or 
were over 55 years of age, and had either osteoporosis or osteopenia as classified by a T-score of less 
than -1. No power calculations were provided. The primary outcome of the study was BMD which 
was measured by dual energy X-ray absorptiometry (DXA) at the screening visit and at the end of the 
study (i.e. at month 12) at the lumbar region (L2-L4) and at the left hip region (femoral neck). In 
addition, bone turnover markers (i.e. serum C-terminal propeptide of Type I collagen, urinary 
pyridinium crosslinks) were measured at month 3 and month 6. The groups were compared using the 
Mann Whitney test. There were no statistically significant differences for percent changes in BMD at 
either site (i.e. lumbar region or femoral neck) between the groups. There were no differences in bone 
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turnover markers between the groups. The Panel notes that this study did not show an effect of the 
Padina pavonica-extract in Dictyolone
®
 on BMD. 
In another randomised, open label, parallel human study (Galea, 2009) 40 post-menopausal women 
were randomised into two groups to receive daily for 12 months 200 mg Padina pavonica-extract in 
Dictyolone
®
 (mean age 61.7 ± 5.4 years, mean age of menopause 49.1 ± 4.6 years) or 450 mg calcium 
carbonate (control group, mean age 60.5 ± 7.5 years, mean age of menopause 50.1 ± 2.7 years). The 
same protocol as for the above study was followed except that BMD measurements were performed 
three times, i.e. at the screening (= baseline), and at month 6 and month 12. Bone turnover markers 
were not assessed in this study. Two women dropped out of the study. The groups were compared 
using the Mann Whitney test, including results from the 38 women who completed the study. For the 
analysis, absolute values (in g/cm
2
) of BMD were transformed to percent changes of BMD prior to 
hypothesis testing. After 12 months, the BMD was increased (as percent change from baseline) in the 
group which had consumed the Padina pavonica-extract in Dictyolone
®
 in lumbar spine (mean ± SD: 
+ 0.39 ± 2.96 %, p = 0.033) and in the femoral neck (+ 0.52 ± 3.10 %, p = 0.024) when compared 
with the control group (- 1.41 ± 2.58 % and - 1.81 ± 2.33 % for the BMD in lumbar spine and femoral 
neck, respectively). The Panel noted that the repeated measures design of the study was not taken into 
consideration in the analysis and that the absolute values of the data were transformed to percent 
changes which could have had an influence on the outcome of the analysis. Therefore, EFSA 
requested the applicant to provide an analysis with non-transformed (i.e. absolute) values and taking 
into account the design (i.e. repeated measures) of the study. EFSA also requested the applicant to 
provide information on the precision of the DXA measurements carried out in the study, and invited 
the applicant to comment on the size of the observed effect in relation to the range of error inherent in 
the test itself. In reply, the applicant submitted an analysis of variance (ANOVA) which compared the 
absolute values of BMD of the two study groups at the three time points (i.e. baseline, month 6 and 
month 12). There were no statistically significant differences between the placebo and the 
Padina pavonica-group at any time point. When the variables were transformed to percent changes 
from baseline to month 12, the ANOVA resulted in a statistically significant difference between the 
placebo and the Padina pavonica-group at the femoral neck (mean ± SD: 0.52 ± 3.10 %, p = 0.012) 
but not at the lumbar spine. The repeated measures design was not taken into account in the analyses. 
The applicant did not provide details on the precision of the DXA measurements. The Panel notes the 
limitations of the statistical analyses performed by the applicant (i.e. transformation of data, lack of 
baseline adjustments in the analysis of absolute values, lack of consideration of the repeated measures 
design of the study) and that the requested re-analysis of the data addressing these limitations was not 
presented by the applicant. The Panel also notes that the results of the different statistical analyses, 
i.e. percent change in BMD analysed with the Mann Whitney test and ANOVA, and absolute values 
of BMD analysed with ANOVA, were inconsistent both between the different statistical tests and 
between bone sites investigated. The Panel considers that this study did not show an effect of the 
Padina pavonica-extract in Dictyolone
®
 on BMD. 
The provided animal studies (Gutierrez et al., 2005, 2006a, b, 2011) did not evaluate BMD. The 
in vitro studies measured calcium accumulation in primary and cell-line osteoblasts (Serrar et al., 
unpublished) and described the patented method (FR 2 827 303; US 7,122,337 B2) referred to in 
section 1 (Gutierrez, 2006). 
In weighing the evidence, the Panel took into account that the two human studies from which 
conclusions could be drawn for the scientific substantiation of the claim did not show an effect of the 
Padina pavonica-extract in Dictyolone
®
 on BMD. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Padina pavonica-extract in Dictyolone
®
 and an increase (or reduced loss) in BMD. 
Padina pavonica-extract in Dictyolone® and bone mineral density  
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, Padina pavonica-extract in Dictyolone®, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect is “improves bone density”. The target population proposed by the 
applicant is the general population. An increase (or reduced loss) in BMD is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of Padina 
pavonica-extract in Dictyolone
®
 and an increase (or reduced loss) in BMD. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Padina pavonica-extract in Dictyolone
®
 and an increase in bone mineral 
density pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0378_MT). 
February 2013. Submitted by ICP Ltd. 
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ABBREVIATIONS 
ANOVA  analysis of variance 
BMD   bone mineral density 
DXA   dual energy X-ray absorptiometry 
